4. CONCLUSION
We present a rare case of IDDVT that was potentially attributed to adenomyosis-associated hypercoagulability and travel-related blood stasis. This case study highlights the importance of etiologic investigation and treatment in the management of thrombotic complications. A comprehensive analysis of previously documented cases suggests that CA125 may serve as a promising biomarker for predicting recurrent or systemic thromboembolism in patients with adenomyosis. Additionally, it is noteworthy that the risk window for thrombotic events in patients with adenomyosis may extend beyond the menstrual period, suggesting a longer duration of susceptibility. Therefore, adenomyosis should be regarded as a potential risk factor for thromboembolism. Aggressive thrombotic risk assessment should be considered as part of clinical practice for patients with this condition, particularly those presenting with severe symptoms and significantly elevated CA125 levels.